Crystal structure of the pyrochlore oxide superconductor KOs2_2O6_6

We report the single-crystal X-ray analysis of the structure of the pyrochlore oxide superconductor KOs$_2$O$_6$. The structure was identified as the $\beta$-pyrochlore structure with space group $Fd\bar{3}m$ and lattice constant $a$ = 10.089(2)~\AA at 300 K: the K atom is located at the 8$b$ site, not at the 16$d$ site as in conventional pyrochlore oxides. We found an anomalously large atomic displacement parameter $U_\mathrm{iso}$ = 0.0735(8)~\AA$^2$ at 300 K for the K cation, which suggests that the K cation weakly bound to an oversized Os$_{12}$O$_{18}$ cage exhibits intensive rattling, as recently observed for clathrate compounds. The rattling of A cations is a common feature in the series of $\beta$-pyrochlore oxide superconductors AOs$_2$O$_6$ (A = Cs, Rb and K), and is greatest for the smallest K cation.Comment: 5 pages, 5 figures, to appear in J. Solid. State. Che

Chemical trends of superconducting properties in pyrochlore oxides

Chemical trends of fundamental superconducting parameters and normal-state properties are described for a family of pyrochlore oxide superconductors. Particularly, the change of Tc from 1.0 K for alpha-pyrochlore Cd2Re2O7 to 3.3 K (A = Cs), 6.3 K (Rb), and 9.6 K (K) for beta-pyrochlore AOs2O6 is discussed on the basis of the conventional BCS scheme. Enhanced Tc and anomalous features observed for KOs2O6 are ascribed to low-energy phonons probably coming from the rattling of the K cations.Comment: 8 pages, to be published in the Proceedings of M2S-HTSC2006 (Physica C

Interface analysis between GSVML and HL7 version 3

AbstractIn order to realize gene-based medicine, a number of key challenges must be overcome. Construction of infrastructure capable of integrating genetic and clinical information is one of those challenges. The Genomic Sequence Variation Markup Language (GSVML) and the Health Level Seven Version 3 (HL7v3) are important electronic data exchange standards for clinical genome infrastructure, and compatibility between these two standards will promote the above integration. In this study, we analyzed the interface between GSVML and HL7v3, primarily for the Clinical Genomics Domain, from a view of the GSVML, and were able to create a blueprint for a functional interface between GSVML and HL7v3. We expect that these analytical results will help accelerate the realization of gene-based medicine